Filters

20172

More filters

20232
Reset filters

Settings

Author: Bornhäuser, Martin × Author: Werner, Carsten × End date: 2023 × Start date: 2023 × End date: 2019 × Start date: 2017 × DDC: 610 × Type: Text × WGL Institute: IPF ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    A three-dimensional ex vivo tri-culture model mimics cell-cell interactions between acute myeloid leukemia and the vascular niche
    (Pavia : Ferrata Storti Foundation, 2017) Bray, Laura J.; Binner, Marcus; Körner, Yvonne; von Bonin, Malte; Bornhäuser, Martin; Werner, Carsten
    Ex vivo studies of human disease, such as acute myeloid leukemia, are generally limited to the analysis of two-dimensional cultures which often misinterpret the effectiveness of chemotherapeutics and other treatments. Here we show that matrix metalloproteinase-sensitive hydrogels prepared from poly(ethylene glycol) and heparin functionalized with adhesion ligands and pro-angiogenic factors can be instrumental to produce robust three-dimensional culture models, allowing for the analysis of acute myeloid leukemia development and response to treatment. We evaluated the growth of four leukemia cell lines, KG1a, MOLM13, MV4-11 and OCI-AML3, as well as samples from patients with acute myeloid leukemia. Furthermore, endothelial cells and mesenchymal stromal cells were co-seeded to mimic the vascular niche for acute myeloid leukemia cells. Greater drug resistance to daunorubicin and cytarabine was demonstrated in three-dimensional cultures and in vascular co-cultures when compared with two-dimensional suspension cultures, opening the way for drug combination studies. Application of the C-X-C chemokine receptor type 4 (CXCR4) inhibitor, AMD3100, induced mobilization of the acute myeloid leukemia cells from the vascular networks. These findings indicate that the three-dimensional tri-culture model provides a specialized platform for the investigation of cell-cell interactions, addressing a key challenge of current testing models. This ex vivo system allows for personalized analysis of the responses of patients’ cells, providing new insights into the development of acute myeloid leukemia and therapies for this disease.
  • Thumbnail Image
    Item
    Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
    ([Erscheinungsort nicht ermittelbar] : Impact Journals LLC, 2017) Bachmann, Dominik; Aliperta, Roberta; Bergmann, Ralf; Feldmann, Anja; Koristka, Stefanie; Arndt, Claudia; Loff, Simon; Welzel, Petra; Albert, Susann; Kegler, Alexandra; Ehninger, Armin; Cartellieri, Marc; Ehninger, Gerhard; Bornhäuser, Martin; von Bonin, Malte; Werner, Carsten; Pietzsch, Jens; Steinbach, Jörg; Bachmann, Michael
    Recent treatments of leukemias with T cells expressing chimeric antigen receptors (CARs) underline their impressive therapeutic potential but also their risk of severe side effects including cytokine release storms and tumor lysis syndrome. In case of cross-reactivities, CAR T cells may also attack healthy tissues. To overcome these limitations, we previously established a switchable CAR platform technology termed UniCAR. UniCARs are not directed against typical tumor-associated antigens (TAAs) but instead against a unique peptide epitope: Fusion of this peptide epitope to a recombinant antibody domain results in a target module (TM). TMs can cross-link UniCAR T cells with tumor cells and thereby lead to their destruction. So far, we constructed TMs with a short half-life. The fast turnover of such a TM allows to rapidly interrupt the treatment in case severe side effects occur. After elimination of most of the tumor cells, however, longer lasting TMs which have not to be applied via continous infusion would be more convenient for the patient. Here we describe and characterize a TM for retargeting UniCAR T cells to CD19 positive tumor cells. Moreover, we show that the TM can efficiently be produced in vivo from producer cells housed in a sponge-like biomimetic cryogel and, thereby, serving as an in vivo TM factory for an extended retargeting of UniCAR T cells to CD19 positive leukemic cells.